Nurix Therapeutics, Inc.

The Shelf Registration Statement, which included a base prospectus, allowed the Company to offer and sell up to $ 450.0 million of the Company s registered common stock, preferred stock, debt securities, warrants, subscription rights and/or units or any combination of securities described in the prospectus in one or more offerings.

SEC original ↗Nurix Therapeutics, Inc. — 10-Q Quarterly report10-QOct 13, 2026

The Automatic Shelf Registration Statement, which includes a base prospectus, allows the Company at any time to offer and sell the Company s registered common stock, preferred stock, debt securities, warrants, subscription rights and/or units or any combination of securities described in the prospectus in one or more offerings.

SEC original ↗Nurix Therapeutics, Inc. — 10-Q Quarterly report10-QOct 13, 2026

The Company also makes certain commencement date estimates for its leases, including the incremental borrowing rate, the expected lease term and the fair value of the leased asset.

SEC original ↗Nurix Therapeutics, Inc. — 10-Q Quarterly report10-QOct 13, 2026

The Company s marketable securities consist of debt securities issued by highly rated corporate entities, the U.

SEC original ↗Nurix Therapeutics, Inc. — 10-Q Quarterly report10-QOct 13, 2026

Moreover, the Company is subject to risks and uncertainties as a result of global business, political and macroeconomic events and conditions, including increasing financial market volatility and uncertainty, inflation, interest rate fluctuations, uncertainty with respect to the federal budget and debt ceiling and potential government shutdowns related thereto, potential instability in the global banking system, cybersecurity events, the impact of war or military conflict, including regional conflicts around the world, and public health pandemics.

SEC original ↗Nurix Therapeutics, Inc. — 10-Q Quarterly report10-QOct 13, 2026

(Nasdaq NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today reported financial results for the fiscal quarter ended August 31, 2025, and highlighted significant progress across its clinical programs and strategic collaborations.

SEC original ↗Nurix Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 9, 2025

Nurix is conducting a Phase 1a 1b clinical trial, including a Phase 1b expansion cohort focused on patients with diffuse large B-cell lymphoma and mantle cell lymphoma.

SEC original ↗Nurix Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 9, 2025

Continued pipeline advancement of strategic collaborations with Gilead, Sanofi and Pfizer Nurix and Sanofi continue to advance the STAT6 degrader, NX-3911, in IND-enabling studies and future updates are anticipated.

SEC original ↗Nurix Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 9, 2025

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases.

SEC original ↗Nurix Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 9, 2025

Forward-looking statements reflect Nurix s current beliefs, expectations, and assumptions regarding the future of Nurix s business, its future plans and strategies, its development plans, its preclinical and clinical results, future conditions and other factors Nurix believes are appropriate in the circumstances.

SEC original ↗Nurix Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 9, 2025

Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix s actual activities and results to differ materially from those expressed in any forward-looking statement.

SEC original ↗Nurix Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 9, 2025

In some cases, you can identify forward-looking statements by such terminology as believe, may, will, potentially, estimate, continue, anticipate, intend, could, would, project, plan, expect and similar expressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these words.

SEC original ↗Nurix Therapeutics, Inc. — 10-Q Quarterly report10-QOct 13, 2026

These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the section titled Risk Factors and elsewhere in this Quarterly Report on Form 10-Q.

SEC original ↗Nurix Therapeutics, Inc. — 10-Q Quarterly report10-QOct 13, 2026

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events.

SEC original ↗Nurix Therapeutics, Inc. — 10-Q Quarterly report10-QOct 13, 2026

RISK FACTOR SUMMARY Our business is subject to a number of risks and uncertainties, including those risks discussed at length below.

SEC original ↗Nurix Therapeutics, Inc. — 10-Q Quarterly report10-QOct 13, 2026

We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on our business.

SEC original ↗Nurix Therapeutics, Inc. — 10-Q Quarterly report10-QOct 13, 2026